Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3856130
Max Phase: Preclinical
Molecular Formula: C91H121N19O32S2
Molecular Weight: 2057.20
Molecule Type: Small molecule
Associated Items:
ID: ALA3856130
Max Phase: Preclinical
Molecular Formula: C91H121N19O32S2
Molecular Weight: 2057.20
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CSCC[C@H](NC(C)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)NCCCC(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(N)=O
Standard InChI: InChI=1S/C91H121N19O32S2/c1-46(77(128)99-61(40-72(119)120)84(135)98-54(26-27-70(115)116)79(130)104-62(41-73(121)122)85(136)101-58(37-49-22-24-51(113)25-23-49)82(133)107-65(45-111)90(141)108-31-11-18-66(108)76(92)127)95-88(139)67-19-12-32-109(67)91(142)68-20-13-33-110(68)89(140)56(29-35-144-4)97-69(114)21-10-30-93-78(129)60(39-71(117)118)103-87(138)64(43-75(125)126)105-81(132)57(36-48-14-6-5-7-15-48)100-86(137)63(42-74(123)124)106-83(134)59(38-50-44-94-53-17-9-8-16-52(50)53)102-80(131)55(28-34-143-3)96-47(2)112/h5-9,14-17,22-25,44,46,54-68,94,111,113H,10-13,18-21,26-43,45H2,1-4H3,(H2,92,127)(H,93,129)(H,95,139)(H,96,112)(H,97,114)(H,98,135)(H,99,128)(H,100,137)(H,101,136)(H,102,131)(H,103,138)(H,104,130)(H,105,132)(H,106,134)(H,107,133)(H,115,116)(H,117,118)(H,119,120)(H,121,122)(H,123,124)(H,125,126)/t46-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-/m0/s1
Standard InChI Key: FIMCRJCXWPVSJJ-DXFSJPQPSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 2057.20 | Molecular Weight (Monoisotopic): 2055.7866 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Attwood MR, Conway EA, Dunsdon RM, Greening JR, Handa BK, Jones PS, Jordan SC, Keech E, Wilson FX. (1997) Peptide based inhibitors of interleukin-8: structural simplification and enhanced potency, 7 (4): [10.1016/S0960-894X(97)00036-X] |
Source(1):